Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Sales0,132,6151,5101212347
EBITDA-245-323--353-261-285
Operating profit (EBIT)-248-329-371-359-272-172
Pre-Tax Profit (EBT)-246-318-197-349-250-129
Net income-246-302-198-345-250-130
P/E ratio-11,3-6,51-11,0-8,90-13,2-26,6
EPS ( $ )-6,21-7,12-3,97-6,72-4,55-2,25
Dividend per Share ( $ )------
Yield------
Reference price ( $ )70.3146.3843.4859.8259.8259.82
Announcement Date02/16/2017
09:05pm
02/20/2018
09:46pm
02/19/2019
09:01pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Debt------
Finance380244460163234164
Operating income (EBITDA)-245-323--353-261-285
Leverage
(Debt/EBITDA)
------
Capital Expenditure10,22,795,2719,330,044,9
Book Value Per Share (BVPS)11,8 $8,68 $12,0 $6,99 $6,80 $-
Cash Flow per Share-4,07 $-5,98 $--5,59 $-3,88 $-
Announcement Date02/16/2017
09:05pm
02/20/2018
09:46pm
02/19/2019
09:01pm
---
Balance Sheet Analysis
Assessed data source :
© 2019 Thomson Reuters
Financial Ratios

Size 2019e 2020e
Capitalization 3 068 M$ -
Entreprise Value (EV) 2 905 M$ 2 833 M$
Valuation 2019e 2020e
P/E ratio (Price / EPS)
Capitalization / Revenue 30,3x 14,5x
EV / Revenue 28,6x 13,4x
EV / EBITDA -8,22x -10,8x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 8,56x 8,79x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -354% -128%
operating Leverage (Delta EBIT / Delta Sales) 0,03x 0,22x
Net Margin (Net Profit / Revenue) -340% -118%
ROA (Net Profit / Asset) -63,5% -62,9%
ROE (Net Profit / Equities) -79,1% -80,2%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   19,0% 14,1%
Cash Flow / Sales -283% -93,7%
Capital Intensity (Assets / Sales) 5,36x 1,87x
Financial Leverage (Net Debt / EBITDA) 0,46x 0,90x
EPS & Dividend